July 13, 2019 : Issue #998

TOP STORIES — Diabetes News and Research: ADA 2019

CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients?

Caution for Using SGLT-2 Inhibitors in Type 1 Diabetes

Maternal Diabetes and the Risk of Autism in Offspring

There are a lot of direct to consumer ads on TV these days. There is a lot of cultural diversity in the patients portrayed, and that lends itself to the assumption that these medications have the same effects across all racial segments. When you look deeper into the studies you often find the number of minority participants to be quite small. This could make a difference when we focus in on CHF, as only one medication, Bidil, has ever had a study focused on treating CHF in African Americans.

This week Amber Satz, PharmD Candidate, LECOM School of Pharmacy, has an interesting review of the possibility that the claims of CHF protection from GLP-1 Agonists and SGLT-2 Inhibitors may be misleading.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

The FDA has issued alerts on Medtronic’s 600-series MiniMed insulin pumps to warn patients that the devices’ keypad buttons could temporarily become “unresponsive” when air pressure changes quickly, which normally happens during flight takeoff and landing. The alerts, classified as a class II recall by the FDA, apply to the MiniMed 620G, 630G, 640G and 670G models.

Claims of improved cardiovascular outcomes from GLP-1 agonists and SGLT2 inhibitors not proven significant for black patients.

There is currently a huge unmet need for non-insulin add on therapy in type 1 diabetes, but are SGLT inhibitors the right drug for the job?

The influence of diabetes during pregnancy and the risk of autism.

Researchers studied 375 adults who were involved in various physical activities and published the results in the journal Obesity.  The study aimed to evaluate whether consistency in time of day that moderate‐ to vigorous‐intensity physical activity (MVPA) is performed relates to MVPA levels among successful weight loss maintainers. Participants (n = 375) reporting MVPA on ≥ 2 d/wk completed measures of temporal consistency in physical activity (PA) (> 50% of MVPA sessions per week occurring during the same time window: early/late morning, afternoon, or evening), PA levels, PA automaticity, and consistency in cues underlying PA habit formation (e.g., location).  Most (68.0%) participants reported temporally consistent MVPA. These individuals reported higher MVPA frequency (4.8 ± 1.6 vs. 4.4 ± 1.5 d/wk; P = 0.007) and duration (median [IQR]: 350.0 [200.0‐510.0] vs. 285.0 [140.0‐460.0] min/wk; P = 0.03), and they were more likely to achieve the national MVPA guideline (≥ 150 min/wk) than temporally inconsistent exercisers (86.3% vs. 74.2%, P = 0.004). Among temporally consistent exercisers, 47.8% were early‐morning exercisers; MVPA levels did not differ by time of day of routine MVPA performance (P > 0.05). Greater automaticity and consistency in several cues were related to greater MVPA among all participants This study found that successful weight loss maintainers who reported temporal consistency in PA engaged in more MVPA than maintainers with more temporally variable exercise routines. Additionally, greater automaticity and greater consistency in cues for PA were related to greater PA levels, especially regarding PA frequency during the week. While a large proportion of temporally consistent exercisers were early‐morning exercisers, suggesting a potential benefit of early‐morning PA for maintaining a regular PA routine, the specific time of routine PA (e.g., early morning vs. evening) among temporally consistent exercisers was not related to PA levels. Among those who reported a temporally consistent PA routine, early morning was the most common time that exercise was performed, followed by evening. Taken together, the findings suggest that exercising at the same time of day, regardless of whether it is during the morning, afternoon, or evening, may help with achieving higher PA levels and greater weight loss.   journal Obesity

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Marian Ayad, BPharm, PharmD candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Kassey  James, Pharm.D. Candidate, LECOM School of Pharmacy

Maya Rudolph, PharmD Candidate, Florida A&M University College of Pharmacy & Pharmaceutical Sciences

Amber Satz, PharmD Candidate, LECOM School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.